Recombinant Human Interleukin-11 Combination Low-dose Rituximab in Immune Thrombocytopenia

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2011
The purpose of this study is to determine whether Recombinant Human Interleukin-11 (rhIL-11) Combination Low-dose Rituximab prednisone are effective and safe in the management of Steroid-Resistant/Relapsed Immune Thrombocytopenia (ITP).
Epistemonikos ID: 689e4fa24190e78563ce113b4c11393a77a6b1b3
First added on: May 06, 2024